Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study

2021256 citationsJournal Articlebronze Open Access

Authors

Mario Tumbarello · Università Cattolica del Sacro Cuore

Francesca Raffaelli · Istituti di Ricovero e Cura a Carattere Scientifico

Maddalena Giannella · University of Bologna

Elisabetta Mantengoli · Azienda Ospedaliero-Universitaria Careggi

Alessandra Mularoni · Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione

Mario Venditti · Sapienza University of Rome

Abstract

CAZ-AVI is an important option for treating serious KPC-Kp infections, even when used alone. Further study is needed to explore the drug's seemingly more limited efficacy in LRTIs and potential survival benefits of prolonging CAZ-AVI infusions to ≥3 hours.

Topics & Keywords

Antibiotic Resistance in Bacteria Antibiotics Pharmacokinetics and Efficacy Antibiotic Use and Resistance

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Infectious Diseases

Volume 73, Issue 9, pp. 1664-1676

DOI: 10.1093/cid/ciab176

Field-Weighted Citation Impact: 14.29